¥»¤å­ì¥Z¸ü©ó¦æ¬F°|¸gÀ٫س]©e­û·|¨È¤ÓÀç¹B¨ó½ÕªA°È¤¤¤ß¦b¤@¤E¤E¤C¦~¤C¤ë
¥Xª©ªº¡u¸gªÀªk¨î½×ÂO¡v¡C¤µ¼x±o¸g«Ø·|¦P·N¡A´£¨Ñ¥»¤å¨Ñ¤j²³°Ñ¾\¡C
• ¥»¤å¶È¨Ñ°Ñ¦Ò¡A¥¿½T¸ê®Æ¥H¡u¸gªÀªk¨î½×ÂO¡v²Ä20´Á p.289-316 ¬°·Ç¡C
• ­Y±ýÂà¸ü©ÎÂà¶K¥»¤å¡A½Ð»P¸g«Ø·|ª½±µÁpµ¸¡A¥H¨ú±o®Ñ­±±ÂÅv¦P·N®Ñ¡C
• ­Y±z¹ï¥»¤å¦³¥ô¦ó«Øij¡A½Ð»P¦¶Ãh¯ª¥ý¥Íª½±µÁpµ¸¡C

ºK­n

¤@¤@¥ø·~¥Hºô»Úºô¸ô¦æ¾P¡A¤w¬°²{¤µ¥D­nÁͶաC¦¹¦]¥Hºô»Úºô¸ô´CÅé
¦æ¾P¤£¶È¦¨¥»§C¡BÂX´²©Ê¤j¡A¨ä¦h¼Ë©Ê¥ç¥i­Ý¨ã²{¦³¨ä¥L´CÅ骺ÀuÂI
¡CµM¦]¨äµo®i¨³³t¡A²{¦³³W½d¹ê¤£¨¬¦]À³¡CÃĪ«­¹«~ºô¸ô¦æ¾P¦p¦ó¥¿
½T³W½d¡A«ê¥i§@¬°¦¹Ãþ°ÝÃD°Ñ¦Ò¡C¦¹¦]ÃĪ«­¹«~¦æ¾P¦V¨ü½Ã¥Í¥DºÞºÞ
¨î¡A¦UºØ¼Ð¥Ü¼s§i¦³ªk³W¼Ð·Ç¡C±©¦¹ÃþºÞ¨î¤è¦¡©óºô»Úºô¸ô¤W¡A¬Ò­±
Á{¦ÒÅç¡C·sªºª§Ä³°ÝÃD¦p¡Gºô¸ô¦æ¾P¨s¬°¼Ð¥Ü©Î¼s§i¡A¸ê°T¬°¨ä¥Lºô
¯¸Âà¸ü³sµ²¥i§_­­¨î¡A¸ê°T¦¨¬°®ø¶OªÌª½¾P¤u¨ã¦p¦ó³B²z¡AÁ{§É¸ÕÅç
¸ê°T¬O§_À³¤©¤½¶}¡Aºô¸ô¸ê°T©ó°ê»Ú¬y³q¦p¦óºÞ²z¡C§^¤H¥i»{¦¹¬ÒÄÝ
¸ê°TºÞ²zªº°ÝÃD¡A¦ÓÂåÃĸê°TºÞ²zªº­ì«h¦p¸ê°T¤½¶}­ì«h¡B­«­n©Ê­ì
«h¡B±M·~¤¤¶¡¤H­û­ì«h»P§iª¾¦P·N­ì«h¡A¦p¦ó¾A¥Î©óºô»Úºô¸ô¸ê°T¡A
¦³¨ä°Ñ¦Ò»ù­È¡C¥»¤å¥H¬°ºô¸ô¸ê°T¦]¦¨¥»»P³t«×¯S©Ê¡A¥i±Ä¸ê°T¤½¶}
»P§iª¾¦P·N­ì«h¡C­n¨DÃĪ«­¹«~¾P°âªÌ©ó»Úºô¸ô¦æ¾P®É¡AÀ³´N¾P°âªÌ
©Òª¾¡A¥H®ø¶OªÌ¯à²z¸Ñªº¤è¦¡¬°©Ò¦³¸ê°T¤½¶}¡C¦¹¤G­ì«hªº°õ¦æ¡A¹ê
¥i­ÝÅU¨¥½×¦Û¥Ñ»P®ø¶OªÌÅv§Q«O»Ù¡C¦Ü¨ä¥¼¨Ó¥ßªkªº«Øij¦p¡G¸ê°T¥­
¿Å¡B¦h¤è°Ñ»P¡B±Ð¨|°V½m¡B¦Û«ß¾÷ºc»PºÊµø³q³ø«h´£¥X§@¬°°Ñ¦Ò¡C

Abstracts

Internet Promotion is a new issue of administration. With its characteristics
of low cost and pervasiveness, internet is no doubt one of the most popular
instrument of promotion in the near future. In food and drug promotion on
internet, however, we do see some conflicts to be resolved, such as: (a)
should it be regulated as labeling or advertisement, (b) how to regulate the
new issue of so called "hyperlink", (c) should we regulate direct sales on
internet, (d) should we restrict the dissemination of clinical trial information,
(e) how about international circulation of relevant information. Four rules
regarding the administration of food and drug's information are examined: (a)
fully disclosure rule (b) materiality rule (c) learned intermediary rule (d)
informed consent rule. We see internet promotion should be more conformed
to the rules of fully disclosure and informed consent, when both consumer
protection and free speech issues are concerned. As a result, directions of
legislation are also proposed: (a) balance approach of information regulation
(b) multiple participants (c) education and training (d) self-regulatory
organization (e) market surveillance.

| Drug Liability | MEDSTUFF | Law Journal EXTRA |

| ºô¸ôÂå¾Ç­b¡B¤À¯¸ | ÃÄ«~ | °·±d­¹«~ | ¤Æ§©«~ | Áô§Î²´Ãè | Åé­«±±¨î | §@ªÌ |

ÃĪ«³d¥ô½×¾Â¥D«ù¤H¡G¦¶Ãh¯ª¡@ºô­¶»s§@¡Gºô¸ôÂå¾Ç­b

«Øºc¤é´Á¡G1997/11/01¡@§ó·s¤é´Á¡G1997/11/11

http://www.health.nsysu.edu.tw/fdaglobe/law.htm

mirror site - http://fda.tmc.edu.tw/law.htm

Copyright 1997-1998